U.S. and Europe regulators oppose ‘vertical merger’ of Illumina-Grail. Critics say that will keep cancer detection costs high.
U.S. and Europe regulators oppose ‘vertical merger’ of Illumina-Grail. Critics say that will keep cancer detection costs high.